CJC-1295 w/DAC

CJC-1295 (tetrasubstituted DAC-modified GRF 1-29) 5mg is a high-purity, lab-tested research peptide designed for advanced scientific investigation into growth hormone regulation and related metabolic processes. As a synthetic analog of Growth Hormone Releasing Hormone (GHRH), CJC-1295 has been structurally modified with a Drug Affinity Complex (DAC) to increase its stability and extend its half-life, making it a highly valuable compound for laboratory studies that require prolonged peptide activity in controlled experimental models.

In research settings, CJC-1295 is primarily studied for its ability to stimulate endogenous growth hormone release from the anterior pituitary gland. By promoting pulsatile growth hormone secretion, it allows researchers to explore downstream effects on muscle development, protein synthesis, cellular repair, and overall metabolic function. This makes it a prominent compound in studies related to muscle physiology, tissue regeneration, and age-associated endocrine research.

The peptide’s high purity, ≥98%, ensures consistent and reproducible results, which is critical for accurate analysis of its effects in both in-vitro and in-vivo models. Researchers can investigate how CJC-1295 influences metabolic pathways, body composition, and hormonal signaling without the variability introduced by lower-quality preparations. The extended half-life provided by DAC modification also allows for more precise study of longer-term biological effects without frequent dosing, simplifying experimental design and data collection.

Proper storage and handling are essential to maintain CJC-1295’s integrity. After reconstitution, refrigeration is required to preserve molecular stability over time. CJC-1295 is intended strictly for research purposes only and is not approved for human or veterinary use. By enabling detailed exploration of growth hormone pathways and their physiological impacts, CJC-1295 continues to serve as an important tool in endocrine, metabolic, and muscle-related research, supporting scientific innovation in next-generation peptide studies.